[1] |
|
[2] |
|
[3] |
|
[4] |
MANCIA G, CAPPUCCIO F P, BURNIER M, et al. Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension[J]. J Intern Med, 2023, 294(3):251-268. DOI: 10.1111/joim.13678.
|
[5] |
|
[6] |
VIJAY D, BEDI J S, DHAKA P, et al. Knowledge,attitude,and practices(KAP) survey among veterinarians,and risk factors relating to antimicrobial use and treatment failure in dairy herds of India[J]. Antibiotics, 2021, 10(2):216. DOI: 10.3390/antibiotics10020216.
|
[7] |
国家心血管病中心,国家基本公共卫生服务项目基层高血压管理办公室,国家基层高血压管理专家委员会. 国家基层高血压防治管理指南2020版[J]. 中国医学前沿杂志:电子版, 2021, 13(4):26-37. DOI: 10.12037/YXQY.2021.04-06.
|
[8] |
LEBEAU J P, BIOGEAU J, CARRÉ M, et al. Consensus study to define appropriate inaction and inappropriate inertia in the management of patients with hypertension in primary care[J]. BMJ Open, 2018, 8(7):e020599. DOI: 10.1136/bmjopen-2017-020599.
|
[9] |
AUJOULAT I, JACQUEMIN P, RIETZSCHEL E, et al. Factors associated with clinical inertia:an integrative review[J]. Adv Med Educ Pract, 2014, 5:141-147. DOI: 10.2147/AMEP.S59022.
|
[10] |
PATHAK A, POULTER N R, KAVANAGH M, et al. Improving the management of hypertension by tackling awareness,adherence,and clinical inertia:a symposium report[J]. Am J Cardiovasc Drugs, 2022, 22(3):251-261. DOI: 10.1007/s40256-021-00505-6.
|
[11] |
REBICKI C V M, RYAN B L, RATZKI-LEEWING A, et al. Family physician clinical inertia in managing hypoglycemia[J]. Prim Care Diabetes, 2022, 16(3):417-421. DOI: 10.1016/j.pcd.2022.02.005.
|
[12] |
NELSON-PIERCY C, VLAEV I, HARRIS K, et al. What factors could influence physicians' management of women of childbearing age with chronic inflammatory disease? A systematic review of behavioural determinants of clinical inertia[J]. BMC Health Serv Res, 2019, 19(1):863. DOI: 10.1186/s12913-019-4693-x.
|
[13] |
SHAWAHNA R, KHALAILY S, ABU SALEH D. Promoters of therapeutic inertia in managing hypertension:a consensus-based study[J]. Am J Manag Care, 2021, 27(11):480-486. DOI: 10.37765/ajmc.2021.88775.
|
[14] |
SHAWAHNA R. Scoping and bibliometric analysis of promoters of therapeutic inertia in hypertension[J]. Am J Manag Care, 2021, 27(11):386-394. DOI: 10.37765/ajmc.2021.88782.
|
[15] |
VERHESTRAETEN C, HEGGERMONT W A, MARIS M. Clinical inertia in the treatment of heart failure:a major issue to tackle[J]. Heart Fail Rev, 2021, 26(6):1359-1370. DOI: 10.1007/s10741-020-09979-z.
|
[16] |
KHUNTI S, KHUNTI K, SEIDU S. Therapeutic inertia in type 2 diabetes:prevalence,causes,consequences and methods to overcome inertia[J]. Ther Adv Endocrinol Metab, 2019, 10:2042018819844694. DOI: 10.1177/2042018819844694.
|
[17] |
|
[18] |
CHEW B H, MOHD-YUSOF B N, LAI P S M, et al. Overcoming therapeutic inertia as the Achilles' heel for improving suboptimal diabetes care:an integrative review[J]. Endocrinol Metab, 2023, 38(1):34-42. DOI: 10.3803/EnM.2022.1649.
|
[19] |
ALI D H, KILIÇ B, HART H E, et al. Therapeutic inertia in the management of hypertension in primary care[J]. J Hypertens, 2021, 39(6):1238-1245. DOI: 10.1097/HJH.0000000000002783.
|
[20] |
WANG J G, ZHANG W, LI Y, et al. Hypertension in China:epidemiology and treatment initiatives[J]. Nat Rev Cardiol, 2023, 20(8):531-545. DOI: 10.1038/s41569-022-00829-z.
|
[21] |
|
[22] |
WRZAL P K, BUNKO A, MYAGERI V, et al. Strategies to overcome therapeutic inertia in type 2 diabetes mellitus:a scoping review[J]. Can J Diabetes, 2021, 45(3):273-281.e13. DOI: 10.1016/j.jcjd.2020.08.109.
|
[23] |
|
[24] |
ESCOBAR C, BARRIOS V, ALONSO-MORENO F J, et al. Evolution of therapy inertia in primary care setting in Spain during 2002-2010[J]. J Hypertens, 2014, 32(5):1138-1145;discussion1145. DOI: 10.1097/HJH.0000000000000118.
|
[25] |
SUN Y X, MU J J, WANG D W, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China:an open,cluster randomised trial[J]. Lancet, 2022, 399(10339):1964-1975. DOI: 10.1016/S0140-6736(22)00325-7.
|
[26] |
GEMBILLO G, INGRASCIOTTA Y, CRISAFULLI S, et al. Kidney disease in diabetic patients:from pathophysiology to pharmacological aspects with a focus on therapeutic inertia[J]. Int J Mol Sci, 2021, 22(9):4824. DOI: 10.3390/ijms22094824.
|
[27] |
LEBEAU J P, CADWALLADER J S, VAILLANT-ROUSSEL H, et al. General practitioners' justifications for therapeutic inertia in cardiovascular prevention:an empirically grounded typology[J]. BMJ Open, 2016, 6(5):e010639. DOI: 10.1136/bmjopen-2015-010639.
|
[28] |
GIUGLIANO D, MAIORINO M I, BELLASTELLA G, et al. Clinical inertia,reverse clinical inertia,and medication non-adherence in type 2 diabetes[J]. J Endocrinol Invest, 2019, 42(5):495-503. DOI: 10.1007/s40618-018-0951-8.
|
[29] |
|
[30] |
BRALIĆ L V, BERGMAN MARKOVIĆ B, KRANJČEVIĆ K. Family physician clinical inertia in glycemic control among patients with type 2 diabetes[J]. Med Sci Monit, 2015, 21:403-411. DOI: 10.12659/msm.892248.
|
[31] |
|
[32] |
GIL-GUILLÉN V, OROZCO-BELTRÁN D, MÁRQUEZ-CONTRERAS E, et al. Is there a predictive profile for clinical inertia in hypertensive patients? An observational,cross-sectional,multicentre study[J]. Drugs Aging, 2011, 28(12):981-992. DOI: 10.2165/11596640-000000000-00000.
|